Last reviewed · How we verify
ACAM3000 MVA Vaccine
At a glance
| Generic name | ACAM3000 MVA Vaccine |
|---|---|
| Also known as | Dryvax smallpox vaccine |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ACAM 3000 MVA at Harvard Medical School (PHASE1, PHASE2)
- Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine (PHASE2)
- Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACAM3000 MVA Vaccine CI brief — competitive landscape report
- ACAM3000 MVA Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI